Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealth New England Clinical Trial Coverage | OpenP…
    Ask Trek AI about this page
    CurrentHealth New EnglandPolicy UM383POL

    Clinical Trial - Medical Policy

    Customize your policy alerts

    Sign up for Health-New-England Policy UM383POL alerts

    Get alerted when Policy UM383POL changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for clinical trial participation and routine patient care costs across Health New England Commercial, Medicaid (BeHealthy), and Medicare Advantage lines of business. Commercial and Medicaid cases follow the policy criteria; Medicare follows National Coverage Determination 310.1.

    Policy Summary
    PayerHealth New England
    PolicyClinical Trial - Medical Policy
    Policy CodePolicy UM383POL
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateNot specified
    Key ActionFor Commercial and Medicaid, preauthorize the clinical trial through Health Services Utilization Management and submit clinical evidence showing that the patient meets the applicable criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Approval criteria for Commercial and Medicaid
    12Explicit non-covered conditions
    3Required documentation categories
    310.1Medicare coverage framework

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Clinical trial phases described
    3Lines of business

    Clinical Trial Coverage Criteria

    Commercial and Medicaid Clinical Trial Approval

    Clinical trials are covered for Commercial and Medicaid when ALL five criteria are met:

    ALL of the following

    • The trial meets the definition of a qualified clinical trial under Massachusetts General Laws Chapter 175, Section 110L, and is consistent with Centers for Medicare & Medicaid Services (CMS) and Patient Protection and Affordable Care Act (PPACA) requirements.
    • The trial is preauthorized and reviewed by the Health Services Utilization Management Department.
    • ONE of the following

      • The referring health care professional is a participating provider and has concluded that the individual's participation in the trial would be appropriate.
      • The participant or beneficiary provides medical and scientific information establishing that the individual's participation in the trial would be appropriate.
    • Clinical trial medications are provided by the clinical trial study at no cost to the member or to Health New England.
    • The clinical trial provides a reasonable expectation of medical benefit with a therapeutic intent.

    Medicare Clinical Trial Coverage

    For the Medicare line of business, Health New England follows National Coverage Determination (NCD) 310.1 for routine costs in clinical trials.

    Routine clinical trial costs are covered and governed according to Medicare NCD 310.1, Routine Costs in Clinical Trials.

    The health insurance plan does not cover experimental or investigational treatments, drugs, or procedures.

    An investigational drug or device paid for by the manufacturer, distributor, or provider of the drug or device is not covered.

    Trials designed exclusively to test toxicity or disease pathophysiology are not covered. The trial must have therapeutic intent.

    Trials involving healthy volunteers are not covered.

    Members who are not clinically eligible or qualified for participation in the clinical trial are not covered.

    Members who have not provided informed consent for trial participation are not covered.

    Non-healthcare services that a member may be required to receive as a result of enrollment in the clinical trial are not covered, including meals, transportation, lodging, and personal care services.

    Costs of services provided primarily to meet the needs of the trial are not covered, including tests, measurements, and other services that are typically covered but are provided at a greater frequency, intensity, or duration, such as monthly CT scans for a condition usually requiring only a single scan.

    Services or items specifically excluded in the member's Explanation of Coverage are not covered.

    Services or items that would not be covered if the member were not enrolled in a clinical trial are not covered.

    After the clinical trial ends, coverage is not provided for non-FDA-approved drugs that were provided or made available to an enrollee during a covered clinical trial.

    Non-covered items and services, including items and services that are statutorily prohibited, are excluded.

    Clinical Trial Coding

    HCPCS Codes Related to Clinical TrialHCPCS
    G0293Non-covered surgical procedure(s) using conscious sedation, regional, general or spinal anesthesia in a Medicare qualifying clinical trial, per day.
    G0294Non-covered surgical procedure(s) using either no anesthesia or local anesthesia only, in a Medicare qualifying clinical trial, per day.
    S9988Services provided as part of Phase I trial.
    S9990Services provided as a part of a phase II clinical trial.
    S9991Services provided as a part of Phase III clinical trial.

    Prior Authorization and Documentation

    Prior Authorization

    Preauthorization and Line-of-Business Review

    For Commercial and Medicaid members, the clinical trial must be preauthorized and reviewed by Health Services Utilization Management before coverage can be considered. Medicare follows NCD 310.1 for routine costs in clinical trials.

    • Confirm the member's line of business and apply the applicable review pathway.
    Documentation Required

    Clinical Evidence Required

    The treating physician or primary care provider must submit clinical evidence supporting that the patient meets the applicable clinical criteria. Without this documentation, Health New England cannot properly review the prior authorization request.

    Documentation Required

    Clinical Trial Overview

    Clinical trials are scientific investigations that compare new, untested, or nonstandard treatments with currently accepted standard treatments to evaluate safety and efficacy. Their primary purpose is to improve clinical knowledge and future patient outcomes; improvement for enrolled members is desirable but secondary. Trials generally progress through Phase I safety and dosing studies, Phase II efficacy and safety studies, Phase III confirmatory comparative studies, and Phase IV post-marketing studies.

    Key Clinical Trial and Device Terms

    Informed Consent
    DefinitionThe process of learning the key facts about a clinical trial before deciding whether or not to participate.
    DocumentationInformed consent must be documented in written form.
    LanguageThe written documentation must be provided in the language of the enrollee's choice.
    Placebo
    TypeAn inactive medication or treatment.
    Therapeutic valueHas no intended therapeutic value.
    Clinical-trial use
    Policy Summary
    PayerHealth New England
    PolicyClinical Trial - Medical Policy
    Policy CodePolicy UM383POL
    Change TypeNo material change
    Effective DateNovember 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateNot specified
    Key ActionFor Commercial and Medicaid, preauthorize the clinical trial through Health Services Utilization Management and submit clinical evidence showing that the patient meets the applicable criteria.
    SourceLink
    On This Page
    Clinical Trial Coverage CriteriaClinical Trial CodingPrior Authorization and DocumentationClinical Trial OverviewKey Clinical Trial and Device Terms

    Submit the Study Protocol

    Submit a copy of the clinical trial study protocol, including its documented therapeutic intent.

    Documentation Required

    Outline Coverage Responsibility

    Provide a detailed outline identifying what the trial covers and provides, and which services are being requested for coverage from the health insurance plan.

    Documentation Required

    Written Informed Consent

    Submit documentation of the member's informed consent for participation in the clinical trial consistent with current legal and ethical standards.

    • Consent must be documented in writing and provided in the language of the enrollee's choice.
    Documentation Required

    Submit Clinical Evidence for Review

    The treating physician or primary care provider must submit clinical evidence demonstrating that the patient meets the applicable criteria for the requested treatment, testing, or surgical procedure.

    • Include sufficient clinical information for Health New England's review of the prior authorization request.
    Denial Risk

    Qualified-Trial Requirement

    Coverage may be denied when the trial does not meet the definition of a qualified clinical trial under Massachusetts General Laws Chapter 175, Section 110L, or is inconsistent with applicable CMS and PPACA requirements.

    • The qualified-trial requirement applies to Commercial and Medicaid approval criteria.
    Denial Risk

    No Prior Authorization

    Coverage may be denied if the required preauthorization and Health Services Utilization Management review were not obtained for a Commercial or Medicaid clinical trial.

    • Obtain approval before the member receives services for which coverage is requested.
    Denial Risk

    Participation Appropriateness Not Established

    Coverage may be denied when the member's participation has not been established as appropriate by a participating referring health care professional, or when the participant or beneficiary has not provided medical and scientific information establishing appropriateness.

    • Document the provider determination or the required supporting medical and scientific information.
    Denial Risk

    Trial Medication Cost Assigned to Plan or Member

    Clinical trial medications must be provided by the clinical trial study at no cost to the member or to Health New England. Coverage may be denied when medication costs are assigned to the plan or member.

    • Confirm that the study supplies the clinical trial medications without charge.
    Denial Risk

    No Therapeutic Intent or Expected Benefit

    Coverage may be denied when the clinical trial does not provide a reasonable expectation of medical benefit or lacks therapeutic intent.

    • Trials designed exclusively to test toxicity or disease pathophysiology do not meet this requirement.
    Denial Risk

    Excluded Trial Types or Participants

    The health insurance plan does not cover excluded trial types, products, or participants, including experimental or investigational treatments, drugs, or procedures and investigational drugs or devices paid for by the manufacturer, distributor, or provider.

    • Trials designed exclusively to test toxicity or disease pathophysiology, including trials lacking therapeutic intent.
    • Trials involving healthy volunteers.
    • Members who are not clinically eligible or otherwise qualified to participate.
    • Investigational drugs or devices paid for by the manufacturer, distributor, or provider.
    Denial Risk

    Consent and Trial-Driven Service Exclusions

    Coverage excludes participation when informed consent has not been provided and excludes non-healthcare services or services required primarily because of trial enrollment.

    • Non-healthcare services may include meals, transportation, lodging, and personal care services.
    • Trial-driven services include tests, measurements, or other ordinarily covered services provided at greater frequency, intensity, or duration than medically required.
    Denial Risk

    Benefit and Post-Trial Exclusions

    Coverage remains subject to the member's benefits and applicable law. Excluded items and services include those specifically excluded by the Explanation of Coverage, services that would not be covered outside the trial, post-trial non-FDA-approved drugs provided or made available during a covered trial, and items or services that are statutorily prohibited.

    • A service being medically necessary under clinical review criteria does not by itself establish that it is covered or payable.
    • The member's benefits program governs if it conflicts with this guideline.
    May be provided to participants in a control group instead of an active drug or treatment to assess effectiveness.
    Humanitarian Use Device (HUD)
    DefinitionA medical device intended to benefit patients in the treatment or diagnosis of a disease or condition.
    Patient-population limitationThe disease or condition must affect or be manifested in no more than 8,000 individuals in the United States per year.
    AuthorityThe definition is identified under Section 3052 of the 21st Century Cures Act (Pub. L. No. 114-255).
    Humanitarian Device Exemption (HDE)
    DefinitionA marketing application for a Humanitarian Use Device.
    Effectiveness exemptionAn HDE is exempt from the effectiveness requirements of Sections 514 and 515 of the Federal Food, Drug, and Cosmetic Act.
    RestrictionsAn HDE is subject to certain profit and use restrictions.
    FDA 510(k) Device Clearance
    Submission typeA premarket submission for a medical device.
    FDA notificationDevice manufacturers notify the FDA within ninety (90) days of intent to market a device, allowing the FDA time to research the device and categorize it.
    Clearance standardThe submission demonstrates that the device is at least as safe and effective as another legally marketed device.
    Premarket Approval (PMA)
    Review standardA more stringent FDA review of the device and the supporting research.
    Required evidenceThe research must contain sufficient scientific evidence providing reasonable assurance that the device is safe and effective.
    Intended usesSafety and effectiveness are evaluated for the device's intended uses.